MedTrace Logo

Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years

NCT01671826 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2016-06-24

No results posted yet for this study

Summary

Autologous stem cell transplantation remains the gold standard of treatment for newly diagnosed patients under the age of 65. Even though it is also regularly performed above the age of 65, there are very few data in this patient population. The investigators will capture safety and efficacy data in that setting.

Conditions

  • Newly Diagnosed Myeloma Patient Above 65 Years Old

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Laurent Garderet, MD · Assistance Publique

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2016-09-30
Completion
2016-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01671826 on ClinicalTrials.gov